Voxelotor

Medication used in the treatment of sickle cell disease by increasing the affinity of hemoglobin for oxygen, thereby reducing the sickling of red blood cells and improving their lifespan. Approved by the U.S. Food and Drug Administration (FDA) in November 2019, it helps alleviate symptoms and complications such as pain crises and anemia. Primarily targeted at patients aged 12 years and older suffering from sickle cell disease.